Cognitive functioning following one‐year natalizumab treatment: A non‐randomized clinical trial. (13th September 2017)

• Record Type: Journal Article
• Authors: Rorsman, I.; Petersen, C.; Nilsson, P.C.
• Is Part Of: Acta neurologica Scandinavica. Volume 137:Number 1(2018)
• Page Start: 117
• Page End: 124
• Publication Date: 2017-09-13
• Subjects: addition test -- cognitive function -- multiple sclerosis -- natalizumab -- neuropsychology -- paced auditory serial -- Paced Auditory Serial Addition Test; Neurology -- Periodicals; 616.8
• DOI: 10.1111/ane.12833
• Languages: English
• ISSNs: 0001-6314

Abstract

Abstract : Objectives: Cognitive impairment is common in multiple sclerosis (MS) and can have serious impact on social and occupational functioning. Natalizumab reduces relapse rates, magnetic resonance imaging (MRI) lesions, and progression of disability. Previous studies on cognitive functioning have not based inclusion on cognitive performance criteria. The aim of the present study was to determine any potential natalizumab‐related cognitive effects on MS patients performing below normal limits on neuropsychological testing. Materials and methods: Patients starting natalizumab (n = 21) and a quasi‐control group of stable MS patients (n = 13) on first line disease modifying treatment were included following neuropsychological assessment demonstrating subnormal cognitive performance. Assessment, using ten cognitive variables, was repeated after 12 months. Symptoms of fatigue, anxiety and depression were also examined. Raw scores on the cognitive tests were transformed into Z‐scores based on published age‐corrected normative data. Results: Between‐group analyses on difference Z‐scores (baseline ‐ follow‐up) yielded significant results on Paced Auditory Serial Addition Test‐2 (PASAT‐2) ( P = .008), with the natalizumab group showing larger improvement than quasi control patients. On PASAT‐2, 28, 5% from the natalizumab group demonstrated >1 SD improvement, indicative of clinically meaningful change, compared with none in the quasi control group. Patients receiving natalizumab showed within‐group improvements on six of the ten cognitive variables. There were no group differences in symptoms of fatigue, anxiety or depression. Conclusions: The results demonstrate improvement in information processing speed following 12‐months of natalizumab treatment. The results are interpreted as reflection of anti‐inflammatory properties of natalizumab rather than retest‐ or long‐term restorative effects.